Tandem Diabetes Care (TNDM) Q3 FY2026 earnings: revenue $284 million, up 13.8% on the year

Tandem Diabetes Care Inc. (TNDM) reported revenue of $284 million for Q3 FY2026, the quarter ended 30 September 2026, up 13.8% on the same quarter a year earlier. Net income was -$7 million, and diluted earnings per share $-0.10. The figures are the company's own, from the 10-Q it filed with the SEC on 5 November 2026.

Revenue

$284 million

+13.8% on the year · +11.4% on the quarter

Q4 FY2024Q3 FY2026

Operating margin

-0.8%

-9.2% a year earlier

Q4 FY2024Q3 FY2026

Net income

-$7 million

Q4 FY2024Q3 FY2026

Diluted EPS

-$0.10

Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

What management said

Guidance figures: 8 kept.

Worldwide sales grew 14%: Worldwide sales were $283.7 million, up from $249.3 million, with no currency impact on reported growth; constant currency growth was also 14%.
Operating loss narrowed to $2.4 million: The operating loss was $2.4 million, or negative 1% of sales, against $22.9 million, or negative 9% of sales, a year earlier. Net loss was $7.1 million against $21.2 million.
International sales grew 26%: International sales were $92.6 million, up 26% (27% in constant currency). International pump sales rose 25% and supplies and other sales rose 26%.

Read the earnings call summary

Income statement (profit and loss)

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Revenue	284	255	249	+11.4%	+13.8%
Cost of revenue	123	110	115	+12.3%	+7.2%
Gross profit	160	145	134	+10.8%	+19.5%
Gross margin	56.5%	56.9%	53.9%
Research and development	48.8	46.9	48.7	+4.1%	+0.3%
Selling, general and administrative	114	112	108	+2.1%	+5.1%
Operating income	-2.4	-13.8	-22.9
Operating margin	-0.8%	-5.4%	-9.2%
Interest expense	2.3	2.5	2.1	-5.9%	+11.6%
Pre-tax income	-7.7	-20.7	-25.1
Income tax	-0.6	0.5	-4.0
Net income	-7.1	-21.2	-21.2
Net margin	-2.5%	-8.3%	-8.5%
Diluted EPS	-$0.10	-$0.31	-$0.31

$ million except per share.

Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Operating cash flow	-0.8	-34.6	8.3
Capital expenditure	4.7	4.0	4.1	+15.7%	+14.5%
Free cash flow	-5.5	-38.7	4.2
Free cash flow margin	-1.9%	-15.2%	1.7%
Cash from investing	18.0	-87.3	20.5		-12.4%
Cash from financing	-7.0	2.2	-1.6
Depreciation and amortisation	4.5	4.5	4.5	+1.0%	+0.4%
Share-based compensation	15.9	15.7	21.1	+1.0%	-24.8%
Buybacks	n/a	n/a	0.0
Diluted shares, weighted	70m	69m	68m	+0.9%	+3.0%
Shares outstanding at period end	70m	70m	68m	+0.3%	+2.9%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Shareholders' equity	135	130	133	+3.6%	+1.6%
Debt	603	603	310	+0.1%	+94.9%
Operating lease liabilities	113	116	118	-3.1%	-4.7%
Other liabilities	308	305	314	+1.1%	-1.8%
Total liabilities and equity	1,159	1,154	875	+0.5%	+32.6%
Fixed assets	85.1	84.5	77.9	+0.8%	+9.3%
Investments	370	393	227	-5.8%	+63.0%
Cash and equivalents	72.8	62.8	91.9	+16.0%	-20.8%
Receivables	180	162	126	+11.1%	+42.9%
Inventory	143	135	137	+5.9%	+4.3%
Other assets	308	317	214	-2.7%	+43.7%
Total assets	1,159	1,154	875	+0.5%	+32.6%

Questions

What was Tandem Diabetes Care's revenue in Q3 FY2026?

Tandem Diabetes Care (TNDM) reported revenue of $284 million for Q3 FY2026, the quarter ended 30 September 2026, up 13.8% on the same quarter a year earlier.

How much did Tandem Diabetes Care earn in Q3 FY2026?

Net loss for Q3 FY2026 was $7 million, and the diluted loss per share $0.10.

When did Tandem Diabetes Care report Q3 FY2026 results?

Tandem Diabetes Care filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 5 November 2026.

Quarterly results, the last 20 quarters

	Q4 FY2021	Q1 FY2022	Q2 FY2022	Q3 FY2022	Q4 FY2022	Q1 FY2023	Q2 FY2023	Q3 FY2023	Q4 FY2023	Q1 FY2024	Q2 FY2024	Q3 FY2024	Q4 FY2024	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025	Q1 FY2026	Q2 FY2026	Q3 FY2026
Revenue	210	176	200	205	221	169	196	186	197	192	222	244	283	234	241	249	290	247	255	284
Cost of revenue	96.3	84.8	98.3	100	105	86.5	94.2	95.9	104	97.0	109	119	125	116	115	115	123	110	110	123
Gross profit	114	91.1	102	104	116	82.9	102	89.8	93.3	94.7	113	125	157	118	126	134	167	137	145	160
Gross margin	54%	52%	51%	51%	52%	49%	52%	48%	47%	49%	51%	51%	56%	51%	52%	54%	58%	55%	57%	57%
R&D	29.5	33.2	33.6	36.8	35.6	42.2	42.9	42.0	42.6	46.2	49.3	51.1	52.2	50.2	48.1	48.7	46.1	46.0	46.9	48.8
SG&A	71.5	73.3	80.6	84.1	97.7	89.8	97.6	79.3	85.8	90.1	94.2	99.6	106	114	110	108	113	108	112	114
Operating income	12.7	-15.3	-12.2	-47.5	-17.8	-128	-38.8	-31.5	-35.1	-41.7	-30.8	-26.1	-0.6	-121	-51.8	-22.9	8.3	-17.4	-13.8	-2.4
Operating margin	6%	-9%	-6%	-23%	-8%	-75%	-20%	-17%	-18%	-22%	-14%	-11%	-0%	-52%	-22%	-9%	3%	-7%	-5%	-1%
Interest expense	n/a	n/a	n/a	n/a	n/a	n/a	1.6	4.8	n/a	1.9	1.8	1.9	1.9	1.9	1.9	2.1	2.1	2.2	2.5	2.3
Pre-tax income	11.1	-16.4	-12.9	-47.3	-16.1	-124	-34.6	-30.7	-31.3	-39.5	-29.7	-22.6	0.0	-122	-57.7	-25.1	4.7	-19.9	-20.7	-7.7
Tax rate	3%	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-4619%	n/a	n/a	n/a	113%	n/a	n/a	n/a
Net income	10.8	-14.7	-15.1	-49.0	-15.9	-124	-35.8	-33.0	-30.0	-42.7	-30.8	-23.3	0.8	-131	-52.4	-21.2	-0.6	-20.4	-21.2	-7.1
Net margin	5%	-8%	-8%	-24%	-7%	-73%	-18%	-18%	-15%	-22%	-14%	-10%	0%	-56%	-22%	-8%	-0%	-8%	-8%	-2%
Diluted EPS	$0.16	-$0.23	-$0.24	-$0.76	-$0.25	-$1.92	-$0.55	-$0.51	-$0.46	-$0.65	-$0.47	-$0.35	$0.01	-$1.97	-$0.78	-$0.31	-$0.01	-$0.30	-$0.31	-$0.10
Operating cash flow	19.6	13.8	6.9	23.9	5.8	-18.3	-6.3	0.1	-7.2	-8.0	-5.3	26.8	10.7	-18.3	-9.5	8.3	9.8	11.1	-34.6	-0.8
Capital expenditure	5.7	2.6	12.1	13.7	5.6	8.8	7.4	5.4	5.2	4.5	6.5	5.2	3.1	3.0	6.2	4.1	6.7	6.3	4.0	4.7
Free cash flow	13.9	11.2	-5.2	10.2	0.2	-27.2	-13.7	-5.3	-12.4	-12.5	-11.7	21.5	7.6	-21.2	-15.7	4.2	3.1	4.8	-38.7	-5.5
Buybacks	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	30.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n/a	n/a	n/a
Shares outstanding	64m	64m	64m	64m	65m	65m	65m	65m	66m	65m	65m	66m	66m	67m	68m	68m	68m	69m	70m	70m
Filing	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q

Each quarter as filed, linked to its filing.

Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 30 September 2026, filed 5 November 2026: the filing.